SGEN - Seattle Genetics, Inc.
| Previous Close | 75.31 |
| Open | 74.01 |
| Bid | 68.00 x 800 |
| Ask | 76.78 x 1400 |
| Day's Range | 73.08 - 75.31 |
| 52 Week Range | 47.75 - 84.37 |
| Volume | 681,161 |
| Avg. Volume | 789,991 |
| Market Cap | 11.88B |
| Beta (3Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings Date | Apr 24, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.36 |
- Zacks•15 days ago
Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com•18 days ago
ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates
Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.
- Investopedia•18 days ago
Pullback Strategies: 10 Stocks That Could Fall the Fastest
These stocks are heavily owned by high-turnover hedge funds, and thus are likely to face severe selling pressure once these funds turn bearish.
- Simply Wall St.•19 days ago
Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic?
Seattle Genetics, Inc.'s (NASDAQ:SGEN): Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. On 31 December 2018, theRead More...
- Business Wire•19 days ago
Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference
Seattle Genetics, Inc. announced today that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m.
- American City Business Journals•19 days ago
Seattle Genetics' new Bothell campus sells for $63M
Commercial real estate investors are seeking out opportunities in places like Bothell where prices are lower relative to much of the rest of the Eastside.
- Zacks•last month
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•last month
Edited Transcript of SGEN earnings conference call or presentation 7-Feb-19 9:30pm GMT
Q4 2018 Seattle Genetics Inc Earnings Call
- Zacks•last month
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
- Business Wire•last month
Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS to include ADCETRIS in combination with AVD in adults patients with previously untreated CD30+ stage IV classical Hodgkin lymphoma .
- Motley Fool•last month
Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today
Earnings took down some key companies today.
- Investor's Business Daily•last month
Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?
Seattle Genetics stock toppled Friday after the biotech met expectations for fourth-quarter sales of cancer treatment Adcetris, but issued soft 2019 guidance for its only approved drug.
- Zacks•last month
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
- Motley Fool•last month
Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed
With shares up 30% year to date, investors may be taking profits.
Motley Fool•last monthSeattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript
SGEN earnings call for the period ending December 31, 2018.
- Benzinga•last month
The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...
- Markit•last month
See what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SGEN totaled $1.34 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•last month
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Seattle Genetics: 4Q Earnings Snapshot
On a per-share basis, the Bothell, Washington-based company said it had a loss of 75 cents. Losses, adjusted for one-time gains and costs, came to 57 cents per share. The results missed Wall Street expectations. ...
- Business Wire•last month
Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
-ADCETRIS® Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter-
- Investing.com•last month
Stocks Moving After Hours: Mattel, Skechers, Columbia Sports
Investing.com - Stocks with big gains and losses after hours:
- Business Wire•2 months ago
Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
Seattle Genetics, Inc. announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m.
- Zacks•2 months ago
What's in the Cards for Glaxo (GSK) This Earnings Season?
Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
